Skip to main content
651 search results for:

Incretin Mimetics 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-01-2021 | Incretin Mimetics | ReviewPaper

    Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis

    Over 350 million adults are currently at high risk of developing type 2 diabetes (T2D), one of the most global prevalent diseases in the twenty-first century [ 1 ]. It is urgent that more collective, multi-sectoral action should be taken to improve …

  2. 01-12-2018 | OriginalPaper

    Microvascular Density and Circulating Endothelial Progenitor Cells Before and After Treatment with Incretin Mimetics in Diabetic Patients

    Diabetes is associated with an increased risk of cardiovascular events and complications which are not completely justified with the simultaneous presence of hypertension or dyslipidemia. Endothelial dysfunction represents an important risk factor …

  3. 01-07-2013 | News

    Debate continues over safety of incretin mimetics

    Incretin mimetics, which include glucagon-like peptide (GLP)-1 receptor agonists (such as exenatide and liraglutide), and dipeptidylpeptidase (DPP)-4 inhibitors (such as alogliptin and sitagliptin), are considered a major advancement in the …

  4. 01-03-2013 | News

    Incretin mimetics potential link with pancreatic pre-cancer

  5. 01-12-2013 | News

    Incretin mimetics: pancreatitis identified in daily clinical practice

  6. 01-09-2013 | OriginalPaper

    Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?

    Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are incretin-derived glucose-lowering agents that have been used for the treatment of type 2 diabetes since 2007. Agents such as exenatide (short-acting and once weekly preparations) …

  7. Diabetology | Journal

    Cardiovascular Diabetology

    First in the field to exclusively cover the link between diabetes and cardiovascular disorders, Cardiovascular Diabetology is the leading, international open access journal specifically dedicated to exploring the interrelationship between heart …

  8. Diabetology | Journal

    Acta Diabetologica

    Acta Diabetologica is a journal that publishes reports of experimental and clinical research on diabetes mellitus and related metabolic diseases. Original contributions on biochemical, physiological, pathophysiological and clinical aspects of …

  9. Diabetology | Journal

    Diabetologia

    Clinical, Translational and Experimental Diabetes and Metabolism

    Diabetologia is the official journal of the European Association for the Study of Diabetes (www.easd.org). We publish peer-reviewed, original research articles about clinical or experimental aspects of diabetes, together with editorials, commentaries, reviews, debates and letters.

  10. Open Access 19-08-2023 | Albuminuria | ReviewPaper

    Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy

    Glucagon-like peptide-1 receptor agonists (GLP-1RAs, incretin mimetics) and dipeptidyl peptidase-4 inhibitors (DPP-4is, incretin enhancers) are glucose-lowering therapies with proven cardiovascular safety, but their effect on microvascular disease …

  11. 01-06-2024 | Breast Cancer | OriginalPaper

    Glucagon-like peptide-1 analogs activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells

    Breast cancer (BC) is associated with type 2 diabetes mellitus (T2DM) and obesity. Glucagon-like peptide (GLP)-1 regulates post-prandial insulin secretion, satiety, and gastric emptying. Several GLP-1 analogs have been FDA-approved for the …

  12. 01-05-2023 | Type 2 Diabetes | ReviewPaper

    Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes

    Type 2 diabetes mellitus (T2DM) is a chronic progressive disease and its mortality and morbidities are rising at alarming rates [ 1 ]. Dipeptidyl peptidase-4 (DPP-4) inhibitors (formally known as gliptins) belong to the class of incretin mimetics [ …2

  13. Open Access 04-04-2024 | Obesity | ReviewPaper

    Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes

    The discovery of long-acting incretin receptor agonists represents a major stride forward in tackling the dual epidemic of obesity and diabetes. Here we outline the evolution of incretin-based pharmacotherapy, from exendin-4 to the discovery of …

  14. 02-05-2024 | Incretin Mimetics | News | Article

    GLP-1 receptor agonists not associated with increased risk for thyroid cancer

    Initiating treatment with a GLP-1 receptor agonist does not raise the risk for thyroid cancer 'substantially', compared with beginning DPP-4 inhibitor treatment.

  15. 15-04-2024 | Obesity | Clinical Trial Summary | Article
    Updated April 2024

    At a glance: The STEP trials

    A round-up of the STEP phase 3 clinical trials evaluating the weekly injectable GLP-1 receptor agonist semaglutide in people with obesity.

  16. 01-03-2024 | Obesity | News | Article

    Survodutide induces weight loss

    Survodutide has been shown to reduce bodyweight in people without diabetes who have overweight or obesity.

  17. 12-02-2024 | Diabetes Therapy | News | Article

    Pros and cons of GLP-1 receptor agonists for type 2 diabetes

    A comprehensive network meta-analysis has validated the efficacy of 15 GLP-1 receptor agonists for the treatment of type 2 diabetes, but also highlighted the risk for gastrointestinal adverse events.

  18. Open Access 12-03-2024 | Diabetic Nephropathy | Review

    Nephroprotective effects of incretin-based therapies

    Cardiovascular outcome trials indicate that incretin-based therapies have renal benefits beyond their glucose-lowering efficacy. But what is the evidence regarding the nephroprotective effects of these anti-diabetes compounds?

  19. 07-02-2024 | Diabetes Therapy | News | Article

    SGLT2 inhibitors lower kidney stone risk in type 2 diabetes

    Sodium-glucose cotransporter inhibitors reduce the risk for developing kidney stones more than two other commonly used treatments for type 2 diabetes.

  20. 22-04-2024 | Semaglutide | Online First

    Semaglutide attenuates pathological electrophysiological remodeling in diabetic cardiomyopathy via restoring Cx43 expression

    The prevalence of diabetes mellitus (DM) keeps increasing globally, with approximately 10% of the world’s population (537 million people) living with diabetes as estimated by the International Diabetes Federation in 2019, and it is predicted that …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.